2 weeks Ago By ABMN Staff
PureTech Health plc ( NASDAQ:PRTC – Get Free Report ) shares gapped up prior to trading on Friday . The stock had previously closed at $20.69, but opened at $21.
63. PureTech Health shares last traded at $21.25, with a volume of 9,730 shares traded.
Wall Street Analysts Forecast Growth Several equities analysts recently weighed in on PRTC shares. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of PureTech Health in a research note on Monday, September 9th.
They set an “outperform” rating and a $45.00 target price on the stock. Check Out Our Latest Analysis on PRTC PureTech Health Price Performance Institutional Inflows and Outflows An institutional investor recently bought a new position in PureTech Health stock.
AWM Investment Company Inc. bought a new stake in PureTech Health plc ( NASDAQ:PRTC – Free Report ) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,900 shares of the company’s stock, valued at approximately $197,000.
Institutional investors own 0.04% of the company’s stock. PureTech Health Company Profile ( Get Free Report ) PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. Featured Stories Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
